Summit Therapeutics Inc. (SMMT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 500K 1M 1.5M Q2 '19: 156K Q3 '19: 148K Q1 '20: 324K Q2 '20: 170K Q3 '20: 181K Q4 '20: 185K Q1 '21: 192K Q2 '21: 57K Q3 '21: 1.3M Q4 '21: 251K Q1 '22: 250K Q2 '22: 235K Q3 '22: 220K Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q3 '24: 0 Q4 '24: 0 Q3 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q4 '24

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-600M -400M -200M 0 200M 400M 600M Q1 '20: -9.3M Q2 '20: -15.4M Q3 '20: -16.9M Q4 '20: -11.6M Q1 '21: -16.9M Q2 '21: -23.7M Q3 '21: -19.5M Q4 '21: -26M Q1 '22: -22.2M Q2 '22: -12.7M Q3 '22: -16.9M Q4 '22: -20.3M Q1 '23: -537.2M Q2 '23: -15.8M Q3 '23: -20.5M Q4 '23: -36.2M Q1 '24: -42.4M Q2 '24: -59.6M Q3 '24: -58.4M Q4 '24: -65.6M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Net Income Quarterly

-600M -400M -200M 0 200M 400M 600M Q3 '21: -19.6M Q4 '21: -27.1M Q1 '22: -21.4M Q2 '22: -16.8M Q3 '22: -21.4M Q4 '22: -19.2M Q1 '23: -542.4M Q2 '23: -14.7M Q3 '23: -21.3M Q4 '23: -36.6M Q1 '24: -43.5M Q2 '24: -60.4M Q3 '24: -56.3M Q4 '24: -61.2M Q1 '25: -62.9M Q2 '25: -565.7M Q3 '25: -231.8M Q4 '25: -219.2M Q1 '26: -189.4M Q2 '26: -215.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -23.6M Q4 '21: -9.2M Q1 '22: -19M Q2 '22: -19.2M Q3 '22: -8.6M Q4 '22: 5.2M Q1 '23: -13.1M Q2 '23: -29.3M Q3 '23: -14.9M Q4 '23: -19.5M Q1 '24: -30.1M Q2 '24: -33M Q3 '24: -30.3M Q4 '24: -48.7M Q1 '25: -61.2M Q2 '25: -66.7M Q3 '25: -93.1M Q4 '25: -101.9M Q1 '26: -122.3M Q2 '26: -141.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -23.6M Q4 '21: -9.3M Q1 '22: -19.4M Q2 '22: -19.5M Q3 '22: -8.6M Q4 '22: 5.2M Q1 '23: -13.2M Q2 '23: -29.3M Q3 '23: -14.9M Q4 '23: -19.5M Q1 '24: -30.1M Q2 '24: -33.1M Q3 '24: -30.4M Q4 '24: -48.7M Q1 '25: -61.6M Q2 '25: -66.7M Q3 '25: -93.2M Q4 '25: -102.1M Q1 '26: -122.5M Q2 '26: -142M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 300M 600M 900M Q1 '20: 67.2M Q2 '20: 67.2M Q3 '20: 67.2M Q1 '21: 82.8M Q2 '21: 92.1M Q3 '21: 99M Q1 '22: 140M Q2 '22: 140.1M Q3 '22: 208.9M Q1 '23: 378.2M Q2 '23: 697.7M Q3 '23: 697.7M Q1 '24: 701.8M Q2 '24: 707.9M Q3 '24: 726.7M Q1 '25: 738.1M Q2 '25: 742.6M Q3 '25: 743.4M Q1 '26: 775.5M Q2 '26: 778.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.80 -1.20 -0.60 0.00 0.60 1.20 1.80 Q4 '20: -0.76 Q1 '21: -0.88 Q2 '21: -0.92 Q3 '21: -0.86 Q4 '21: -0.68 Q1 '22: -0.62 Q2 '22: -0.47 Q3 '22: -0.37 Q4 '22: -0.41 Q1 '23: -1.69 Q2 '23: -1.59 Q3 '23: -1.52 Q4 '24: -0.32 Q1 '25: -0.35 Q2 '25: -1.02 Q3 '25: -1.25 Q4 '25: -1.44 Q1 '26: -1.59 Q2 '26: -1.11 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.